Plerixafor Injection Dealers in Mumbai

• Brand Name: Celon
• Form: celon
• Country of Origin: India
• Material: Below 25 degree
• Strength: 20MG/ML
• Medicine Type: CELON LABORATORIES
• Usage/Application: Application
• Application: Molding Injections
• Warranty: 1year

Celrixafor Injection is used in Autologous stem cell transplant. It is a procedure in which certain blood cells are removed from the body and then returned to the body after the chemotherapy and/or radiation in patients with certain cancers.

• Packaging Type: Vial, Box
• Form: Injection
• Composition: Plerixafor
• Manufacturer: Metta Life
• Treatment: Peripheral Blood Stem Cell Mobilization,Which Is Important As a Source Of Hematopoietic Stem Cells
• Packaging Size: 1.2 ml
• Shelf Life: 2 Years
• Strength: 24 mg

• Country of Origin: India
• Shelf Life: 2years
• Color: White
• Form: Powder
• Formula: C28H54N8
• Moisture: Min 2-8%

Medicine Brand REXAFOR Medicine Form Injection Medicine Name Plerixafor Injection Medicine Strength 20 mg / ml (24 mg / 1.2 ml) Packaging Type Single Dose vial

• Packaging Type: Vial, Box
• Form: Injection
• Brand: Mozifor
• Dose/Strength: 20 mg/ ml
• Composition: Plerixafor 24mg/1.2ml

• Formula: C28H54N8
• Other Names: JM 3100, AMD3100
• Pharmacopoeia: IH
• Trade Name: Mozobil
• Elimination Half-Life: 3–5 hours
• ATC Code: L03AX16 (WHO)
• ChEBI ID: 125354

Plerixafor is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients into the bloodstream. The stem cells are then extracted from the blood and transplanted back to the patient. The drug was developed by AnorMED, which was subsequently bought by Genzyme.

• Country of Origin: India

Celrixafor is the Generic version of Mozobil™ (PLERIXAFOR) On December 15, 2008, the U. S. Food and Drug Administration (FDA) approved plerixafor, solution for subcutaneous injection, (Mozobil™, Genzyme Corp.) for use in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Peripheral blood stem cell mobilization, which is important as a source of hematopoietic stem cells for transplantation, is usually performed using granulocyte colony-stimulating factor (G-CSF), but is ineffective in around 15 to 20% of patients. Combination of G-CSF with Celrixafor (Plerixafor)   increases the percentage of persons that respond to the therapy and produce enough stem cells for transplantation

• Strength: 20 mg
• Packaging Type: Vial
• Storage: Store at room temperature (25 C). Do not freeze.
• Manufacturer: THERDOSE PHARMA PRIVATE LIMITED (INDIA)
• Brand Name: Plerixa

• Form: Injection
• Usage: Hospital
• Dose/Strength: 24 mg/1.2 ml
• Composition: Plerixafor